TABLE 5.
Post‐treatments after disease progression
| Post‐treatment | Overall N = 63 | ECOG‐PS 2 N = 38 | ECOG‐PS ≥3 N = 25 |
|---|---|---|---|
| Chemotherapy, n (%) | |||
| Received second‐line chemotherapy | 22 (34.9) | 14 (36.8) | 8 (32.0) |
| Platinum‐based doublet | 8 | 5 | 3 |
| Single agents | 14 | 9 | 5 |
| Amrubicin | 10 | 6 | 4 |
| Irinotecan | 3 | 2 | 1 |
| Topotecan | 1 | 1 | 0 |
| Received third‐line chemotherapy | 6 (9.5) | 4 (10.5) | 2 (8.0) |
| Received fourth‐line chemotherapy | 1 (1.6) | 1 (2.6) | 0 |
| BM recurrences, n (%) | 22 (34.9) | 16 (42.1) | 6 (24.0) |
| New lesions | 17 | 12 | 5 |
| Exacerbation of existing lesions | 3 | 2 | 1 |
| New + exacerbation | 2 | 2 | 0 |
| Received radiation therapy for BM recurrences, n (%) | 10 (14.3) | 7 (18.4) | 3 (12.0) |
| WBRT | 8 | 6 | 2 |
| SRT/SRS | 2 | 1 | 1 |
Abbreviations: BM, brain metastases; ECOG‐PS, Eastern Cooperative Oncology Groups Performance Status; SRS, stereotactic radiosurgery; SRT, stereotactic radiation therapy; WBRT, whole brain radiotherapy.